Titlebook: Immunoconjugate Therapy of Hematologic Malignancies; Steven T. Rosen,Timothy M. Kuzel Book 1993 Springer Science+Business Media New York 1

五個(gè)

書目名稱Immunoconjugate Therapy of Hematologic Malignancies影響因子(影響力)




書目名稱Immunoconjugate Therapy of Hematologic Malignancies影響因子(影響力)學(xué)科排名




書目名稱Immunoconjugate Therapy of Hematologic Malignancies網(wǎng)絡(luò)公開度




書目名稱Immunoconjugate Therapy of Hematologic Malignancies網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Immunoconjugate Therapy of Hematologic Malignancies被引頻次




書目名稱Immunoconjugate Therapy of Hematologic Malignancies被引頻次學(xué)科排名




書目名稱Immunoconjugate Therapy of Hematologic Malignancies年度引用




書目名稱Immunoconjugate Therapy of Hematologic Malignancies年度引用學(xué)科排名




書目名稱Immunoconjugate Therapy of Hematologic Malignancies讀者反饋




書目名稱Immunoconjugate Therapy of Hematologic Malignancies讀者反饋學(xué)科排名

IRS

CURL

Treatment of leukemia with radiolabeled monoclonal antibodies,rate that has been achieved by combining chemotherapy with external beam whole-body irradiation and bone marrow transplantation in a small number of eligible patients is based on eradicating virtually all normal and neoplastic hematopoietic cells. Such an approach implicitly acknowledges that select

好忠告人

淘氣

New approaches to radiolabeling monoclonal antibodies,sults have been obtained in both radioimmunoimaging and radioimmunotherapy trials, several problems related to the biodistribution of radiolabeled monoclonal antibodies have been observed, including the relatively low accumulation of activity in tumor and the excessive accumulation of activity in no

脆弱么

Hyperalgesia

Immunotoxins for the therapy of graft versus host disease,es, immunologic disorders, and genetic disorders. Acute graft versus host disease (GVHD), a potential major complication of allogeneic bone marrow transplants, remains a limitation to this approach. In the setting where an HLA-matched sibling is the marrow donor, 30–50% of patients undergoing marrow

Insufficient

,Recombinant fusion toxins — A new class of targeted biologic therapeutics, of a toxin, typically diphtheria toxin or Pseudomonas exotoxin [.,.]. These single-chain polypeptides are built upon a product template contained within each toxin molecule. The toxin molecule has three functional domains: (1) the receptor binding domain or targeting ligand recognizes and attaches

反復(fù)拉緊

Chimeric antibodies for the treatment of hematologic malignancy, the major goals of oncology is to refocus this capacity to mediate tumor specific destruction; to recreate, in effect, the inflammatory response that the tumor has avoided. Such a strategy demands the ability to activate and expand adequate quantities of effector cells (and proteins), to recruit th

cutlery

Use of bispecific antibodies in the therapy of tumors,immune disease, graft rejection, and cancer. Although these immunoconjugates have considerable potential, problems associated with their toxicity have slowed their clinical application. Unconjugated MoAb, although not associated with as severe side effects, have generally had little biological activ